plastid single-subunit type RNA polymerase binding

Binding to a single subunit plastid RNA polymerase enzyme, which is composed of a single catalytic subunit similar to the RNA polymerase enzymes from phages T3, T7, and SP6.


TFIIIB-class transcription factor complex binding

biolink:MolecularActivity biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Binding to a general RNA polymerase III transcription factor belonging to the TFIIB complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase III.


C2 domain binding

Binding to the C2 domain of a protein, a protein structural domain involved in targeting proteins to cell membranes.


cholecystokinin receptor binding

Binding to a cholecystokinin receptor.


talin binding

Binding to a talin, a family of related cytoskeletal proteins that play a role in assembly of actin filaments and migration of various cell types.


type 2 metabotropic glutamate receptor binding

Binding to a type 2 metabotropic glutamate receptor.


prolactin-releasing peptide receptor binding

Binding to a prolactin-releasing peptide receptor.


glycosylation-dependent protein binding

Binding to a protein upon glycosylation of the target protein.


BH1 domain binding

Binding to a BH1 protein domain, present in Bcl-2 family members. Proteins that act as inhibitors of apoptosis harbour at least three BH domains: BH1, BH2 and BH3; the BH1 and BH2 domains are found in all death antagonists of the Bcl-2 family but only in one class of death agonists.


EP3 subtype prostaglandin E2 receptor binding

Binding to an EP3 subtype prostaglandin E2 receptor.


type III interferon binding

Binding to a type III interferon. Interferon lambda is the only member of the type III interferon found so far.


protein dimerization activity

The formation of a protein dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.


peptidyl-proline 4-dioxygenase binding

Binding to a peptidyl-proline 4-dioxygenase.


Edg-4 lysophosphatidic acid receptor binding

Binding to an Edg-4 lysophosphatidic acid receptor.


mitochondrial single-subunit type RNA polymerase binding

Binding to a single subunit mitochondrial RNA polymerase enzyme, which is composed of a single catalytic subunit similar to the RNA polymerase enzymes from phages T3, T7, and SP6.


chemokine (C-C motif) ligand 7 binding

Binding to chemokine (C-C motif) ligand 7.


RNA polymerase II complex recruiting activity

Binding to an RNA polymerase II (Pol II) complex, typically composed of twelve subunits, and with another protein, macromolecule, or complex, permitting those molecules to function in a coordinated way in order to facilitate the aggregation, arrangement and bonding together of proteins on an RNA polymerase II promoter DNA to form the transcriptional preinitiation complex (PIC), the formation of which is a prerequisite for transcription by RNA polymerase.


CH domain binding

Binding to a calponin homology protein domain, a domain of 100 residues that occurs in signaling and cytoskeletal proteins.


cadherin binding involved in cell-cell adhesion

Any cadherin binding that occurs as part of the process of cell-cell adhesion.


vacuolar sorting signal binding

Binding to a vacuolar sorting signal, a specific peptide sequence that acts as a signal to localize the protein within the vacuole.


interleukin-19 binding

Binding to interleukin-19.


C-X3-C chemokine binding

Binding to a C-X3-C chemokine; C-X3-C chemokines have three amino acids between the first two cysteines of the characteristic four-cysteine motif.


collectin binding

Binding to a collectin, a member of a group of structurally related pattern recognition molecules characterized by having a carbohydrate recognition domain of the C-type lectin family at the C-terminus and a collagenous domain at the N-terminus.


secretin receptor binding

Binding to a secretin receptor.


RBL family protein binding

Binding to a member of the rhamnose-binding lectin (RBL) family, a family of animal lectins that show specific binding activities to L-rhamnose or D-galactose.


calcitonin binding

Binding to calcitonin, a peptide hormone responsible for reducing serum calcium levels by inhibiting osteoclastic bone reabsorption and promoting renal calcium excretion. It is synthesized and released by the C cells of the thyroid.


neuromedin U receptor binding

Binding to one or more specific sites on a neuromedin U receptor.


K6-linked polyubiquitin modification-dependent protein binding

Binding to a protein upon poly-ubiquitination formed by linkages between lysine residues at position 6 in the target protein.


eukaryotic initiation factor 4G binding

Binding to eukaryotic initiation factor 4G, a polypeptide factor involved in the initiation of ribosome-mediated translation.


interleukin-18 binding

Binding to interleukin-18.


P2Y11 nucleotide receptor binding

Binding to a P2Y11 nucleotide receptor.


MDA-5 binding

Binding to MDA-5, a cytosolic pattern recognition receptor that initiates an antiviral signaling pathway upon binding to viral dsRNA.


cargo receptor ligand activity

The activity of a gene product that interacts with a cargo receptor and initiates endocytosis.


Binding to a protein upon phosphorylation of the target protein.


type 1 metabotropic GABA receptor binding

Binding to a type 1 metabotropic GABA receptor.


type 2C serotonin receptor binding

Binding to a type 2C serotonin receptor.


melanin-concentrating hormone receptor binding

Binding to a melanin-concentrating hormone receptor.


Edg-1 sphingosine 1-phosphate receptor binding

Binding to an Edg-1 sphingosine 1-phosphate receptor.


K11-linked polyubiquitin modification-dependent protein binding

Binding to a protein upon poly-ubiquitination formed by linkages between lysine residues at position 11 in the target protein.


type 5B serotonin receptor binding

Binding to a type 5B serotonin receptor.


neuromedin U binding

Interacting selectively and non-covalently and stoichiometrically with neuromedin U, a hypothalamic peptide involved in energy homeostasis and stress responses.


gonadotropin-releasing hormone receptor binding

Binding to a receptor for gonadotropin-releasing hormone (GnRH), a peptide hormone that is synthesized and released by the hypothalamus and is responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary.


type 1 neuromedin U receptor binding

Binding to a type 1 neuromedin U receptor.


platelet activating factor receptor binding

Binding to a platelet activating factor receptor.


parathyroid hormone receptor binding

Binding to a parathyroid hormone receptor.


nuclear mineralocorticoid receptor binding

Binding to a nuclear mineralocorticoid receptor.


identical protein binding

Binding to an identical protein or proteins.


macrophage migration inhibitory factor binding

Binding to the cytokine, macrophage migration inhibitory factor.


exogenous protein binding

Binding to a protein or protein complex from a different species, for example a pathogen molecule binding to a host protein.


granulocyte macrophage colony-stimulating factor complex binding

Binding to a granulocyte macrophage colony-stimulating factor complex.


corticotropin-releasing hormone binding

Binding to corticotropin-releasing hormone, a polypeptide hormone involved in the stress response. It is released by the hypothalamus and stimulates the release of corticotropin by the anterior pituitary gland.


pentraxin binding

Binding to a pentraxin, a member of a family of inflammatory proteins with a radially symmetric arrangement of five identical, noncovalently linked chains in a pentagonal array.


A2B adenosine receptor binding

Binding to an A2B adenosine receptor.


cell adhesive protein binding involved in Purkinje myocyte-ventricular cardiac muscle cell communication

Binding to a protein or protein complex that results in the connection of a Purkinje myocyte with an ventricular cardiac muscle cell and contributes to the communication between the two cells.


bacterial-type RNA polymerase core enzyme binding

Binding to a bacterial-type RNA polymerase core enzyme, typically consisting of two alpha, one beta, one beta prime, and one omega subunit.


high molecular weight B cell growth factor receptor binding

Binding to a high molecular weight B cell growth factor receptor.


TFIIH-class transcription factor complex binding

Binding to a general RNA polymerase II transcription factor belonging to the TFIIH complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.


STAT family protein binding

Binding to a member of the signal transducers and activators of transcription (STAT) protein family. STATs are, as the name indicates, both signal transducers and transcription factors. STATs are activated by cytokines and some growth factors and thus control important biological processes including cell growth, cell differentiation, apoptosis and immune responses.


Hsp27 protein binding

Binding to Hsp27 proteins, a lightweight heat shock protein.


BIR domain binding

Binding to a Baculovirus Inhibitor of apoptosis protein Repeat (BIR) domain.


RNA polymerase II C-terminal domain binding

Binding to the C-terminal domain (CTD) of the largest subunit of RNA polymerase II. The CTD is comprised of repeats of a heptapeptide with the consensus sequence YSPTSPS. The number of repeats varies with the species and a minimum number of repeats is required for RNAP II function.


interleukin-12 alpha subunit binding

Binding to the alpha subunit of interleukin-12.


prostacyclin receptor binding

Binding to a prostacyclin receptor.


chloroplast targeting sequence binding

Binding to a chloroplast targeting sequence, a specific peptide sequence that acts as a signal to localize the protein within the chloroplast.


interleukin-13 binding

Binding to interleukin-13.


cell adhesion receptor activity

The binding by a cell-adhesion protein on the cell surface to an extracellular matrix component, to mediate adhesion of the cell to the external substrate or to another cell and to initiate intracellular signaling. Cell adhesion receptors include integrins and cadherins.


EP2 subtype prostaglandin E2 receptor binding

Binding to an EP2 subtype prostaglandin E2 receptor.


somatostatin binding

Binding to somatostatin, a polypeptide hormone involved in regulating pancreatic alpha and pancreatic beta cells and controlling growth hormone secretion as well as many other functions. Somatostatin is produced by several cell types including pancreatic delta cells. There are several different mature forms of somatostatin.


fMet-Leu-Phe receptor binding

Binding to a fMet-Leu-Phe receptor.


MHC class II protein binding, via lateral surface

Binding to the lateral surface of major histocompatibility complex class II molecules.


scavenger receptor binding

Binding to scavenger receptors, a family of proteins that are expressed on myeloid cells and are involved in the uptake of effete cellular components and foreign particles.


type 6 metabotropic glutamate receptor binding

Binding to a type 6 metabotropic glutamate receptor.


type 7 metabotropic glutamate receptor binding

Binding to a type 7 metabotropic glutamate receptor.


DH domain binding

Binding to a DH (Dbl homology) domain of a protein. The DH domain contains three structurally conserved regions separated by more variable regions. It is composed of 11 alpha helices that are folded into a flattened, elongated alpha-helix bundle in which two of the three conserved regions, conserved region 1 (CR1) and conserved region 3 (CR3), are exposed near the centre of one surface. CR1 and CR3, together with a part of alpha-6 and the DH/PH (pleckstrin homology) junction site, constitute the Rho GTPase interacting pocket.


type 1 orexin receptor binding

Binding to a type 1 orexin receptor.


complement component C3d binding

Binding to a C3d product of the complement cascade.


translation elongation factor binding

Binding to a translation elongation factor, any polypeptide factor involved in the peptide elongation in ribosome-mediated translation.


single-subunit type RNA polymerase binding

Binding to a single subunit RNA polymerase enzyme, which is composed of a single catalytic subunit similar to the RNA polymerase enzymes from phages T3, T7, and SP6.


interleukin-27 binding

Binding to interleukin-27.


TFIIB-class transcription factor binding

Binding to a general RNA polymerase II transcription factor of the TFIIB class, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.


type 1B serotonin receptor binding

Binding to a type 1B serotonin receptor.


Edg-7 lysophosphatidic acid receptor binding

Binding to an Edg-7 lysophosphatidic acid receptor.


arrestin family protein binding

Binding to a member of the arrestin family, proteins involved in agonist-mediated desensitization of G protein-coupled receptors.


dynein light chain binding

Binding to a light chain of the dynein complex.


type 1 neurotensin receptor binding

Binding to a type 1 neurotensin receptor.


type-III cohesin domain binding

Binding to a type-III cohesin domain of a protein. Type-III cohesin domain is the binding partner of type-III dockerin domain.


peroxisome membrane class-2 targeting sequence binding

Binding to a class II peroxisomal membrane targeting sequence, any of several sequences of amino acids within a protein that can act as a signal for the localization of the protein into the peroxisome membrane in a PEX19-independent manner.


penicillin binding

Binding to penicillin, an antibiotic that contains the condensed beta-lactamthiazolidine ring system.


TFIIIA-class transcription factor binding

Binding to an RNA polymerase III transcription factor of the TFIIIA class, one of the factors involved in formation of the preinitiation complex (PIC) at RNA polymerase III promoters.


DNA binding domain binding

Binding to a protein's DNA binding domain (DBD).


ADP-D-ribose modification-dependent protein binding

Binding to a protein upon ADP-ribosylation of the target protein.


ciliary neurotrophic factor binding

Binding to the cytokine ciliary neurotrophic factor.


orexin receptor binding

Binding to an orexin receptor.


zymogen binding

Binding to a zymogen, an enzymatically inactive precursor of an enzyme that is often convertible to an active enzyme by proteolysis.


EP4 subtype prostaglandin E2 receptor binding

Binding to an EP4 subtype prostaglandin E2 receptor.


FYXD domain binding

Binding to a FXYD domain.


calcium-dependent outer dynein arm binding

Binding to an outer dynein arm in the presence of calcium.


interleukin-33 binding

Binding to interleukin-33.


triacyl lipopeptide binding

Binding to a lipopeptide containing a nonprotein moiety consisting of three acyl groups.


peroxisome matrix targeting signal-2 binding

Binding to a type 2 peroxisome targeting signal, a nonapeptide with a broad consensus sequence of (R/K)-(L/V/I)-(XXXXX)-(H/Q)-(L/A/F).


glial cell-derived neurotrophic factor receptor binding

A growth factor that binds selectively and non-covalently to glial cell-derived neurotrophic factor receptors.


GBD domain binding

Binding to a GTPase protein binding domain (GDB) domain. The GBD is a short motif, including a minimum region of 16 amino acids, identified in proteins that bind to small GTPases such as Cdc42 and Rac.


proctolin receptor binding

Binding to a proctolin receptor.


hepatocyte growth factor binding

Binding to a hepatocyte growth factor.


H9 melatonin receptor binding

Binding to a H9 melatonin receptor.


glucagon receptor binding

Binding to a glucagon receptor.


type 1 member 3 taste receptor binding

Binding to a type 1 member 3 taste receptor.


myosin VI light chain binding

Binding to a light chain of a myosin VI complex.


endocytic targeting sequence binding

Binding to a endocytic signal sequence, a specific peptide sequence, of 4-6 amino acids with an essential tyrosine (Y), found on cytoplasmic tails of some cell surface membrane proteins, which directs internalization by clathrin-coated pits.


MATH domain binding

Binding to a meprin and TRAF homology (MATH) domain.


intercellular adhesion molecule-3 receptor binding

Binding to a receptor for intercellular adhesion molecule-3 (ICAM-3), such as DC-SIGN and LFA-1.


cell adhesive protein binding involved in AV node cell-bundle of His cell communication

Binding to a protein or protein complex that results in the connection of an AV node cell with a bundle of His cell and contributes to the communication between the two cells.


H2 histamine receptor binding

Binding to a H2 histamine receptor.


corazonin receptor binding

Binding to a corazonin receptor.


myosin VI heavy chain binding

Binding to a heavy chain of a myosin VI complex.


MH2 domain binding

Binding to a MH2 (MAD homology 2) protein domain. The MH2 domain is found at the carboxy-terminus of MAD related proteins such as Smads. The MH2 domain mediates interaction with a wide variety of proteins and provides specificity and selectivity to Smad function and also is critical for mediating interactions in Smad oligomers.


RIP homotypic interaction motif binding

Binding to a RIP homotypic interaction motif (RHIM) of a protein. The RHIM is a 16-amino-acid motif found in some members, including RIP3, of a family of related kinases.


interleukin-10 binding

Binding to interleukin-10.


ErbB-4 class receptor binding

Binding to the protein-tyrosine kinase receptor ErbB-4/HER4.


V1B vasopressin receptor binding

Binding to a V1B vasopressin receptor.


MADS box domain binding

Binding to a MADS box domain, a protein domain that encodes the DNA-binding MADS domain. The MADS domain binds to DNA sequences of high similarity to the motif CC[A/T]6GG termed the CArG-box. MADS-domain proteins are generally transcription factors. The length of the MADS-box is in the range of 168 to 180 base pairs.


type 1 member 1 taste receptor binding

Binding to a type 1 member 1 taste receptor.


low molecular weight kininogen binding

Binding to a kininogen of low molecular mass.


type 7 serotonin receptor binding

Binding to a type 7 serotonin receptor.


neuropeptide F receptor binding

Binding to a neuropeptide F receptor.


acetylation-dependent protein binding

Binding to a protein upon acetylation of the target protein.


CRD domain binding

Binding to a CRD (context dependent regulatory) domain, a domain of about 130 residues that is the most divergent region among the LEF/TCF proteins.


nuclear cortisol receptor binding

Binding to a nuclear cortisol receptor.


DNA-binding transcription factor binding

Binding to a DNA-binding transcription factor, a protein that interacts with a specific DNA sequence (sometimes referred to as a motif) within the regulatory region of a gene to modulate transcription.


chemokine (C-C motif) ligand 12 binding

Binding to chemokine (C-C motif) ligand 12.


type 4 neuropeptide Y receptor binding

Binding to a type 4 neuropeptide Y receptor.


linear polyubiquitin binding

Binding to a linear polymer of ubiquitin. Linear ubiquitin polymers are formed by linking the amino-terminal methionine (M1) of one ubiquitin molecule to the carboxy-terminal glycine (G76) of the next.


prostaglandin F2-alpha receptor binding

Binding to a prostaglandin F2-alpha receptor.


farnesylated protein binding

Binding to a farnesylated protein.


pituitary adenylate cyclase-activating polypeptide receptor binding

Binding to a pituitary adenylate cyclase-activating polypeptide receptor.


gastric inhibitory polypeptide receptor binding

Binding to a gastric inhibitory polypeptide receptor.


myosin II head/neck binding

Binding to the head/neck region of a myosin II heavy chain.


type-II dockerin domain binding

Binding to a type-II dockerin domain of a protein. Type-II dockerin domain is the binding partner of type-II cohesin domain.


interleukin-17 binding

Binding to a member of the interleukin-17 family of cytokines.


laminin binding involved in cell-matrix adhesion

Any laminin protein binding that occurs as part of cell-matrix adhesion.


orexigenic neuropeptide QRFP receptor binding

Binding to an orexigenic neuropeptide QRFP receptor.


ciliary targeting signal binding

Binding to a ciliary targeting sequence, a specific peptide sequence that acts as a signal to localize a membrane protein to the ciliary membrane.


gonadotropin-releasing hormone binding

Binding to gonadotropin-releasing hormone (GnRH), a peptide hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is synthesized and released by the hypothalamus.


A3 adenosine receptor binding

Binding to an A3 adenosine receptor.


poly-ADP-D-ribose modification-dependent protein binding

Binding to a protein upon poly-ADP-ribosylation of the target protein.


subtype 3 bombesin receptor binding

Binding to a subtype 3 bombesin receptor.


thioglucosidase binding

Binding to a thioglucosidase enzyme.


Krueppel-associated box domain binding

Binding to a Krueppel-associated box (KRAB) domain of a protein. The approximately 75 amino acid KRAB domain is enriched in charged amino acids, and is found in the N-terminal regions of many zinc finger-containing transcription factors.


Rel homology domain binding

Binding to a Rel Homology Domain (RHD) of a protein. The RHD is found in a family of eukaryotic transcription factors, which includes NF-kappaB, Dorsal, Relish and NFAT.


urea binding

Binding to urea, a water-soluble carboxamide with the structure H2N-CO-NH2.


DDEL sequence binding

Binding to a KDEL sequence, the C terminus tetrapeptide sequence Asp-Asp-Glu-Leu found in proteins that are to be retained in the endoplasmic reticulum.


oxytocin receptor binding

Binding to an oxytocin receptor.


kisspeptin receptor binding

Binding to a kisspeptin receptor.


type 1D serotonin receptor binding

Binding to a type 1D serotonin receptor.


H3K27me3 modified histone binding

Binding to a histone H3 in which the lysine residue at position 27 has been modified by trimethylation.


high mobility group box 1 binding

Binding to high mobility group box 1 (HMBGB1).


adrenomedullin receptor binding

Binding to an adrenomedullin receptor.


type 1 melanin-concentrating hormone receptor binding

Binding to a type 1 melanin-concentrating hormone receptor.


LEM domain binding

Binding to a LEM domain. The LEM domain (for lamina-associated polypeptide, emerin, MAN1 domain) is present in a group of nuclear proteins that bind chromatin through interaction of the LEM motif with the conserved DNA crosslinking protein, barrier-to-autointegration factor (BAF).


syntaxin-3 binding

Binding to a syntaxin-3 SNAP receptor.


thyrotropin-releasing hormone receptor binding

Binding to a receptor for thyrotropin-releasing hormone, a tripeptide hormone that is produced by the hypothalamus and stimulates the release of thyroid-stimulating hormone (TSH) and prolactin by the anterior pituitary.


CAP-Gly domain binding

Binding to a CAP-Gly domain of a protein. The CAP_Gly domain is a conserved, glycine-rich domain of about 42 residues found in some cytoskeleton-associated proteins, and features a novel protein fold containing three beta-sheets.


MHC class I protein binding, via lateral surface

Binding to a major histocompatibility complex class I molecules via the lateral surface.


EGF repeat binding

Binding to Epidermal Growth Factor (EGF) repeats.


type 2 vasoactive intestinal polypeptide receptor binding

Binding to a type 2 vasoactive intestinal polypeptide receptor.


type 5 metabotropic glutamate receptor binding

Binding to a type 5 metabotropic glutamate receptor.


interleukin-25 binding

Binding to interleukin-25.


cannabinoid receptor binding

Binding to a cannabinoid receptor.


cell adhesive protein binding involved in SA cardiac muscle cell-atrial cardiac muscle cell communication

Binding to a protein or protein complex that results in the connection of an SA cardiomyocyte with an atrial cardiomyocyte and contributes to the communication between the two cells.


P2Y2 nucleotide receptor binding

Binding to a P2Y2 nucleotide receptor.


SMC family protein binding

Binding to a protein from the structural maintenance of chromosomes (SMC) family, a group of chromosomal ATPases with a role in mitotic chromosome organization.


AF-1 domain binding

Binding to an AF-1 protein domain, a ligand-independent transactivation domain which is required for the full transcriptional activity of the receptor.


type 5 somatostatin receptor binding

Binding to a type 5 somatostatin receptor.


CD70 receptor binding

Binding to a CD70, a receptor found on the surface of most activated B cells and some activated T cells.


imaginal disc growth factor receptor binding

Binding to an imaginal disc growth factor receptor.


neuregulin binding

Binding to a neuregulin, a member of the EGF family of growth factors.


ubiquitin modification-dependent histone binding

Binding to a histone protein in which a residue has been modified by ubiquitination.


Toll binding

Binding to a Toll protein, a transmembrane receptor.


chemokine (C-C motif) ligand 19 binding

Binding to chemokine (C-C motif) ligand 19.


POU domain binding

Binding to a POU domain of a protein. The POU domain is a bipartite DNA binding domain composed of two subunits separated by a non-conserved region of 15-55 amino acids; it is found in several eukaryotic transcription factors.


C5a anaphylatoxin chemotactic receptor binding

Binding to a C5a anaphylatoxin chemotactic receptor.


Edg-3 sphingosine 1-phosphate receptor binding

Binding to an Edg-3 sphingosine 1-phosphate receptor.


TFIIF-class transcription factor complex binding

Binding to a general RNA polymerase II transcription factor belonging to the TFIIF complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.


type 8 metabotropic glutamate receptor binding

Binding to a type 8 metabotropic glutamate receptor.


eukaryotic initiation factor eIF2 binding

Binding to eukaryotic initiation factor eIF2, a protein complex involved in the initiation of ribosome-mediated translation.


type 3 proteinase activated receptor binding

Binding to a type 3 proteinase activated receptor.


H4 histamine receptor binding

Binding to a H4 histamine receptor.


type 5 neuropeptide Y receptor binding

Binding to a type 5 neuropeptide Y receptor.


growth hormone-releasing hormone receptor binding

Binding to a growth hormone-releasing hormone receptor.


RIG-I binding

Binding to RIG-I, a cytosolic pattern recognition receptor that initiates an antiviral signaling pathway upon binding to viral RNA.


C5L2 anaphylatoxin chemotactic receptor binding

Binding to a C5L2 anaphylatoxin chemotactic receptor.


phosphorylated histone binding

Binding to a histone in which a residue has been modified by phosphorylation.


microtubule lateral binding

Binding to the side of a microtubule.


phytochrome binding

Binding to a phytochrome.


myosin VI head/neck binding

Binding to the head/neck region of a myosin VI heavy chain.


poly-glutamine tract binding

Binding to a polyglutamine tract, i.e. a series of consecutive glutamine residues, in a protein.


interleukin-7 binding

Binding to interleukin-7.


methylation-dependent protein binding

Binding to a protein upon methylation of the target protein.


type 1 member 2 taste receptor binding

Binding to a type 1 member 2 taste receptor.


RHG protein domain binding

Binding to an RHG (reaper/hid/grimm) domain/motif (AKA iap binding motif).


type 2 melanin-concentrating hormone receptor binding

Binding to a type 2 melanin-concentrating hormone receptor.


interleukin-12 beta subunit binding

Binding to the beta subunit of interleukin-12.


muramyl dipeptide binding

Interacting selectively and non-covalently, in a non-covalent manner, with muramyl dipeptide; muramyl dipeptide is derived from peptidoglycan.


interleukin-3 binding

Binding to interleukin-3.


A1 adenosine receptor binding

Binding to an A1 adenosine receptor.


FH1 domain binding

Binding to a FH1 domain of a protein, a proline-rich domain, usually located in front of a FH2 domain.


type 1F serotonin receptor binding

Binding to a type 1F serotonin receptor.


FMN-binding domain binding

Binding to the FMN-binding domain of a protein.


H4K20me3 modified histone binding

Binding to a histone H4 in which the lysine residue at position 20 has been modified by trimethylation.


myosin I binding

Binding to a class I myosin; myosin I heavy chains are single-headed, possess tails of various lengths, and do not self-associate into bipolar filaments.


signaling receptor binding

Binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.


plastid PEP RNA polymerase core enzyme binding

Binding to a bacterial-type plastid PEP RNA polymerase core enzyme, typically consisting of two alpha, one beta, one beta prime, and one double prime subunit.


P2Y1 nucleotide receptor binding

Binding to a P2Y1 nucleotide receptor.


type 4 serotonin receptor binding

Binding to a type 4 serotonin receptor.


sterol-dependent protein binding

Binding to a protein or protein complex in the presence of sterols.


high molecular weight kininogen receptor binding

Binding to a high molecular weight kininogen receptor.


bone sialoprotein binding

Binding to a bone sialoprotein, an extracellular matrix glycoprotein found on the surface of bones and dentin.


glucagon family peptide binding

Binding to a member of the glucagon family peptide hormone (e.g. glucagon, glucagon-like peptides, oxyntomodulin, glicentin, ADCYAP1, GHRH, secretin, VIP, GIP).


motilin receptor binding

Binding to a motilin receptor.


tachykinin receptor binding

Binding to a tachykinin receptor.


phosphopantetheine binding

Binding to phosphopantetheine, the vitamin pantetheine 4'-(dihydrogen phosphate).


interleukin-24 binding

Binding to interleukin-24.


endothelin A receptor binding

Binding to an endothelin A receptor.


neurokinin receptor binding

Binding to a neurokinin receptor.


ghrelin receptor binding

Binding to a ghrelin receptor.


neuropeptide Y receptor binding

Binding to a neuropeptide Y receptor.


delta-type opioid receptor binding

Binding to a delta-type opioid receptor.


myosin II tail binding

Binding to the tail region of a myosin II heavy chain.


taste receptor binding

Binding to a taste receptor.


F-bar domain binding

Binding to an F-BAR domain of a protein, a domain of about 60 residues that occurs in a wide range of cytoskeletal proteins.


gastrin-releasing peptide receptor binding

Binding to a gastrin-releasing peptide receptor.


neurotensin receptor binding

Binding to a neurotensin receptor.


nociceptin receptor binding

Binding to a nociceptin receptor.


interleukin-5 binding

Binding to interleukin-5.


type 1 parathyroid hormone receptor binding

Binding to a type 1 parathyroid hormone receptor.


lutropin-choriogonadotropic hormone receptor binding

Binding to a lutropin-choriogonadotropic hormone receptor.


lipoamide binding

Binding to lipoamide, the functional form of lipoic acid in which the carboxyl group is attached to protein by an amide linkage to a lysine amino group.


type 1 proteinase activated receptor binding

Binding to a type 1 proteinase activated receptor.


serpin family protein binding

Binding to a member of the serpin protein family (serine protease inhibitors or classified inhibitor family I4). Serpins are a broadly distributed family of protease inhibitors that use a conformational change to inhibit target enzymes. They are central in controlling many important proteolytic cascades. The majority of serpins inhibit serine proteases, but serpins that inhibit caspases and papain-like cysteine proteases have also been identified. Rarely, serpins perform a non-inhibitory function; for example, several human serpins function as hormone transporters and certain serpins function as molecular chaperones or tumor suppressors.


adipokinetic hormone receptor binding

Binding to an adipokinetic hormone receptor. Adipokinetic hormones (AKHs) are peptide hormones that are involved in the mobilization of sugar and lipids from the insect fat body during energy-requiring activities such as flight and locomotion. They also contribute to hemolymph sugar homeostasis.


ubiquitin-dependent protein binding

Binding to a protein upon ubiquitination of the target protein.


alpha-latrotoxin receptor binding

Binding to an alpha-latrotoxin receptor.


CD154 receptor binding

Binding to CD154, a receptor found on the surface of some activated lymphocytes.


deaminase binding

Binding to an enzyme that catalyzes the removal of an amino group from a substrate, producing ammonia (NH3).


ganglioside GM3 binding

Binding to ganglioside GM3.


torso binding

Binding to a torso (tor) protein, a receptor tyrosine kinase.


type 2 orexin receptor binding

Binding to a type 2 orexin receptor.


BH4 domain binding

Binding to a BH4 protein domain, present in Bcl-2 family members. All anti-apoptotic proteins contain BH1 and BH2 domains; some also contain an additional N-terminal BH4 domain, which is almost never seen in pro-apoptotic proteins. Loss of the BH4 domain can diminish or abrogate anti-apoptotic function or even impart outright death-promoting properties to the protein.


B2 bradykinin receptor binding

Binding to a B2 bradykinin receptor.


antisigma factor binding

Binding to an antisigma factor, a factor which inhibits the ability of the sigma factor to function as a transcriptional initiator.


kappa-type opioid receptor binding

Binding to a kappa-type opioid receptor.


type 1 neuropeptide Y receptor binding

Binding to a type 1 neuropeptide Y receptor.


H3K9me3 modified histone binding

Binding to a histone H3 in which the lysine residue at position 9 has been modified by trimethylation.


interleukin-16 binding

Binding to interleukin-16.


type 1A melatonin receptor binding

Binding to a type 1A melatonin receptor.


SET domain binding

Binding to a SET domain of a protein. SET domains are named after three Drosophila proteins that contain this domain: Su(var), E(z) and trithorax. SET domains are associated with histone lysine methylation.


high molecular weight kininogen binding

Binding to a kininogen of high molecular mass.


TIMP family protein binding

Binding to a member of the Tissue inhibitors of metalloproteinases (TIMPs) family. TIMPs are endogenous protein regulators of the matrix metalloproteinase (MMPs) family.


neuromedin B receptor binding

Binding to a neuromedin B receptor.


hemoglobin alpha binding

Binding to a hemoglobin alpha chain.


type 1 galanin receptor binding

Binding to a type 1 galanin receptor.


cell adhesive protein binding involved in atrial cardiac muscle cell-AV node cell communication

Binding to a protein or protein complex that results in the connection of an atrial cardiomyocyte with an AV node cell and contributes to the communication between the two cells.


RNA polymerase V core binding

Binding to RNA polymerase V core enzyme, a multisubunit eukaryotic nuclear RNA polymerase found in plants and involved in production of noncoding transcripts at target loci for silencing.


complement component C3dg binding

Binding to a C3dg product of the complement cascade.


small protein activating enzyme binding

Binding to a small protein activating enzyme, such as ubiquitin-activating enzyme.


type 2 cannabinoid receptor binding

Binding to a type 2 cannabinoid receptor.


CNBH domain intrinsic ligand binding

Interacting selectivity and noncovalently with a cyclic nucleotide mimicking protein motif that is part of the same protein. The CNBHD is a domain on KCNH channels that creates a binding pocket on the KCNH channel that resembles the cyclic nucleotide- binding domain on other ion channels. It binds to a peptide motif that is part of the same protein rather than a cyclic nucleotide.


P2Y4 nucleotide receptor binding

Binding to a P2Y4 nucleotide receptor.


bacterial-type RNA polymerase holo enzyme binding

Binding to a component of the basal transcription machinery which is composed of a bacterial-type RNA polymerase core enzyme and a sigma factor, the minimal set of factors required for formation of the preinitiation complex (PIC) by a bacterial-type RNA polymerase.


thyrotropin-releasing hormone binding

Binding to thyrotropin-releasing hormone, a tripeptide hormone that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin by the anterior pituitary and it is produced by the hypothalamus and travels across the median eminence to the pituitary via the pituitary portal system.


wishful thinking binding

Binding to wishful thinking (Wit), a type II bone morphogenic protein receptor.


general transcription initiation factor binding

Binding to a general transcription initiation factor, a protein that contributes to transcription start site selection and transcription initiation.


Binding to succinate-semialdehyde dehydrogenase.


type 3 somatostatin receptor binding

Binding to a type 3 somatostatin receptor.


type-III dockerin domain binding

Binding to a type-III dockerin domain of a protein. Type-III dockerin domain is the binding partner of type-III cohesin domain.


calcitonin family binding

Binding to a member of the calcitonin family (e.g. adrenomedullin, adrenomedullin 2 (intermedin), amylin, calcitonin and calcitonin gene-related peptides (CGRPs)).


type 5A serotonin receptor binding

Binding to a type 5A serotonin receptor.


RNA polymerase III core binding

Binding to an RNA polymerase III core enzyme, a multisubunit eukaryotic nuclear RNA polymerase typically composed of seventeen subunits.


FBXO family protein binding

Binding to a member of the FBXO protein family. Members of this family have an F-box protein motif of approximately 50 amino acids that functions as a site of protein-protein interaction.


myosin head/neck binding

Binding to the head/neck region of a myosin heavy chain.


F-box domain binding

Binding to an F-box domain of a protein.


type 1 vasoactive intestinal polypeptide receptor binding

Binding to a type 1 vasoactive intestinal polypeptide receptor.


interleukin-35 binding

Binding to interleukin-35.


substance K receptor binding

Binding to a substance K receptor.


peroxisome membrane targeting sequence binding

Binding to a peroxisomal membrane targeting sequence, any of several sequences of amino acids within a protein that can act as a signal for the localization of the protein into the peroxisome membrane.


RNA polymerase IV core binding

Binding to RNA polymerase IV core enzyme, a multisubunit eukaryotic nuclear RNA polymerase found in plants and involved in siRNA production.


integrin binding involved in cell-matrix adhesion

Any integrin binding that occurs as part of the process of cell-matrix adhesion.


virus coreceptor activity

Combining with a virus component, and in cooperation with a nearby primary receptor, initiating a change in cell activity.


FHA domain binding

Binding to a FHA domain of a protein. The FHA domain is a phosphopeptide recognition domain found in many regulatory proteins, and consists of approximately 80-100 amino acid residues folded into an 11-stranded beta sandwich.


P2Y9 nucleotide receptor binding

Binding to a P2Y9 nucleotide receptor.


splicing factor binding

Binding to a protein involved in the process of removing sections of the primary RNA transcript to form the mature form of the RNA.


somatostatin receptor binding

Binding to a somatostatin receptor.


vasoactive intestinal polypeptide receptor binding

Binding to a vasoactive intestinal polypeptide receptor.


type 1E serotonin receptor binding

Binding to a type 1E serotonin receptor.


netrin receptor binding

Binding to a netrin receptor.


polo box domain specific binding

Binding to a polo box domain of a protein. The polo box domain is involved in binding substrates of polo kinases.


myosin I light chain binding

Binding to a light chain of a myosin I complex.


type 2 angiotensin receptor binding

Binding to a type 2 angiotensin receptor.


H1 histamine receptor binding

Binding to a H1 histamine receptor.


A2A adenosine receptor binding

Binding to an A2A adenosine receptor.


interleukin-15 binding

Binding to interleukin-15.


calcitonin gene-related peptide binding

Binding to calcitonin gene-related peptide (CGRP).


MH1 domain binding

Binding to a MH1 (MAD homology 1) protein domain. The MH1 domain is found at the amino terminus of MAD related proteins such as Smads and can mediate DNA binding in some proteins. Smads also use the MH1 domain to interact with some transcription factors.


EH domain binding

Binding to an EH domain of a protein. The EH stand for Eps15 homology. This was originally identified as a motif present in three copies at the NH2-termini of Eps15 and of the related molecule Eps15R.


BH2 domain binding

Binding to a BH2 protein domain, present in Bcl-2 family members. Proteins that act as inhibitors of apoptosis harbour at least three BH domains: BH1, BH2 and BH3; the BH1 and BH2 domains are found in all death antagonists of the Bcl-2 family but only in one class of death agonists.


chemokine (C-C motif) ligand 2 binding

Binding to chemokine (C-C motif) ligand 2.


myosin I head/neck binding

Binding to the head/neck region of a myosin I heavy chain.


type II interferon binding

Binding to type II interferon, also known as interferon-gamma.


melatonin receptor binding

Binding to a melatonin receptor.


ELYC domain binding

Binding to a ELYC protein domain. The ELYC domain is an approximately 150 amino acid sequence which contains a highly conserved tetrapeptide sequence, ELYC.


amino-terminal vacuolar sorting propeptide binding

Binding to an amino terminal propeptide, which functions as a sorting signal to sort away the soluble vacuolar protein from Golgi to lytic vacuole via clathrin-coated vesicles.


beta-endorphin binding

Binding to beta-endorphin, a peptide generated by the cleavage of pro-opiomelanocortin.


type 2 proteinase activated receptor binding

Binding to a type 2 proteinase activated receptor.


type 2 cysteinyl leukotriene receptor binding

Binding to a type 2 cysteinyl leukotriene receptor.


X11-like protein binding

Binding to X11-like protein, a neuron-specific adaptor protein.


type-I dockerin domain binding

Binding to a type-I dockerin domain of a protein. Type-I dockerin domain is the binding partner of type-1 cohesin domain.


ubiquitination-like modification-dependent protein binding

Binding to a protein upon modification by a ubiquitin-like protein of the target protein.


Edg-5 sphingosine 1-phosphate receptor binding

Binding to an Edg-5 sphingosine 1-phosphate receptor.


G protein-coupled nucleotide receptor binding

Binding to a G protein-coupled (metabotropic) nucleotide receptor.


mono-ADP-D-ribose modification-dependent protein binding

Binding to a protein upon mono-ADP-ribosylation of the target protein.


protein binding

Binding to a protein.


modification-dependent protein binding

Binding to a protein upon post-translation modification of the target protein.


G protein-coupled GABA receptor binding

Binding to a G protein-coupled (metabotropic) GABA receptor.


disordered domain specific binding

Binding to a disordered domain of a protein.


Cacosmia

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:ThingWithTaxon

A hallucination of an unpleasant odor.


aminodiol

An amino alcohol having two hydroxy functional groups.


protein insertion into ER membrane by stop-transfer membrane-anchor sequence

biolink:BiologicalProcess biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

A process of protein insertion into the endoplasmic reticulum (ER) membrane in which stop-transfer membrane-anchor sequences become an ER membrane spanning helix.


negative regulation of cellular response to amino acid starvation

Any process that stops, prevents or reduces the frequency, rate or extent of a cellular response to amino acid starvation.


chronic lymphocytic leukemia/small lymphocytic lymphoma

An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.


hairy cell leukemia

Hairy cell leukemia (HCL) is a rare type of leukemia in which abnormal B-lymphocytes are present in the bone marrow, spleen and peripheral blood. It is a slowly progressive chronic lymphocytic leukemia (CLL). The name comes from the abnormally shaped lymphocytes with hair-like projections.


intrapelvic lymph node leukemic reticuloendotheliosis


refractory hairy cell leukemia

Hairy cell leukemia that is resistant to treatment.


pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that lacks somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes, implying pregerminal center B-cell origin. Microarray gene expression profiling studies have demonstrated the expression of ZAP-70 gene (Syk family tyrosine kinase) in this subset of CLL/CLL. Patients with this variant of CLL/SLL have an unfavorable prognosis compared to those with somatic hypermutations of the IGH genes, with a median survival of approximately 6-8 years.


chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation

A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) expressing somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes. The recognition of this variant alters the belief that CLL/SLL is always derived from a naive, pregerminal center B-cell. The presence of somatic hypermutations of IGH genes occurs in approximately 50% of CLL/SLL cases and implies a postgerminal center, memory origin. Patients with this variant of CLL/SLL have a favorable prognosis, with a reported median survival of more than 24 years.


hairy cell leukemia variant

Hairy Cell Leukemia variant (HCL-V) is defined as a rare and indolent form of small, mature, B-cell leukemia characterized by splenomegaly, an elevated white blood cell (WBC) count and hyper-cellular bone marrow. HCL-V is more aggressive and resistant to therapy than classical HCL (HCL-C).


superior mesenteric vein

biolink:GrossAnatomicalStructure biolink:AnatomicalEntity biolink:OrganismalEntity biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:PhysicalEssence biolink:SubjectOfInvestigation biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

In anatomy, the superior mesenteric vein (SMV) is a blood vessel that drains blood from the small intestine. At its termination behind the neck of the pancreas, the SMV combines with the splenic vein to form the hepatic portal vein. The SMV lies to the right of the similarly named artery, the superior mesenteric artery, which originates from the abdominal aorta. [WP,unvetted].


Breast Classic Lobular Carcinoma In Situ Type B

Breast classic lobular carcinoma in situ  characterized by the presence of neoplastic cells with nuclei of various sizes and shapes.


Prognostic Stage IIIA Breast Cancer AJCC v8

Stage IIIA includes: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); ( T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma

A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an invasive lobular carcinomatous component.


Localized Breast Carcinoma

Breast carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Invasive Breast Cribriform Carcinoma

An invasive adenocarcinoma of the breast with a favorable clinical outcome, characterized by the presence of a sieve-like or cribriform infiltrating pattern.


Intraductal Micropapillary Breast Carcinoma

Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.


Solid papillary carcinoma in situ of breast

Breast solid papillary carcinoma characterized by the presence of nodules with rounded, well-circumscribed contours and a distribution pattern consistent with an in situ process. (WHO 2019)


Stage IIA Breast Carcinoma

Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Stage IIIC Breast Cancer AJCC v7

Stage IIIC includes: Any T, N3, M0.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast angiosarcoma

A malignant vascular neoplasm arising from the breast.


Invasive Breast Lobular Carcinoma, Solid Variant

A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.


Metastatic Triple-Negative Breast Carcinoma

A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Invasive Breast Lobular Carcinoma with Predominant In Situ Component

A breast carcinoma characterized by the presence of a predominant lobular carcinoma in situ component and a minor component of invasive carcinoma.


Recurrent Malignant Breast Neoplasm

The reemergence of a malignant breast neoplasm after a period of remission.


Invasive Breast Lobular Carcinoma, Alveolar Variant

A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.


Hereditary Female Breast Carcinoma

Breast carcinoma that has developed in female relatives of patients with history of breast carcinoma.


High Grade Ductal Breast Carcinoma In Situ

Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.


Breast Carcinoma Metastatic in the Liver

A carcinoma that originates from the breast and has spread to the liver.


Unresectable HER2-Negative Breast Carcinoma

HER2-negative breast carcinoma that is not amenable to surgical resection.


Histiocytoid Breast Carcinoma

A rare variant of invasive lobular breast carcinoma characterized by the presence of histiocyte-like malignant cells with pale cytoplasm forming sheets or linear patterns. Apocrine differentiation may be present. It usually has an aggressive clinical course.


Squamous Cell Carcinoma In Situ of the Nipple

An intraepidermal squamous cell carcinoma involving the area of the nipple.


malignant neoplasm of breast stage I

Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0).  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T0: No evidence of primary tumor.  N0: No regional lymph node metastasis.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Prognostic Stage 0 Breast Cancer AJCC v8

Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Refractory HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that is resistant to treatment.


Invasive Breast Solid Papillary Carcinoma

Breast solid papillary carcinoma associated with areas featuring strands or large clusters of tumor cells. (WHO 2019)


Breast Florid Lobular Carcinoma In Situ

Breast lobular carcinoma in situ characterized by the presence of neoplastic cells with cytological features identical to classic lobular carcinoma in situ, but with marked distention of terminal ductal lobular units or ducts.


adenocarcinoma of breast with neuroendocrine differentiation

An invasive breast carcinoma characterized by the presence of focal neuroendocrine differentiation.


Metastatic Breast Inflammatory Carcinoma

Inflammatory carcinoma of the breast that has spread from its original site of growth to another anatomic site.


Metastatic Breast Neuroendocrine Tumor G1

A well differentiated neuroendocrine tumor that arises from the breast and has metastasized to other anatomic sites.


Stage IV Breast Cancer AJCC v6 and v7

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 6th and 7th Eds.)


Breast Classic Lobular Carcinoma In Situ

Breast lobular carcinoma in situ characterized by the presence of dyscohesive proliferations of type A and/or type B epithelial cells. Type A cells are small cells with uniform hyperchromatic nuclei, whereas type B cells have slightly larger vesicular nuclei, with mild variability in size and shape and with small nucleoli. The cell populations may be mixed in individual proliferations. (WHO 2019)


Atypical Medullary Breast Carcinoma

An invasive ductal breast carcinoma characterized by the presence of a predominantly syncytial architectural pattern. It may have some, but not all the strictly defined additional morphologic criteria which are necessary for the diagnosis of medullary breast carcinoma (presence of a diffuse lymphoplasmacytic infiltrate, neoplastic round cells with abundant cytoplasm and vesicular nuclei, complete histological circumscription, and absence of glandular or tubular structures). It does not have the relatively favorable outcome that characterizes medullary breast carcinoma.


Breast Periductal Stromal Tumor

A rare, low-grade malignant stromal tumor that arises from the breast. It is characterized by the proliferation of atypical stromal spindle cells that surround benign tubules and ducts in a pericanalicular pattern. Mitotic activity is present. The tumor has a multinodular and infiltrative growth pattern and lacks the leaf-like architecture of phyllodes tumor. Wide excision with negative margins is the treatment of choice.


Primary angiosarcoma of breast

An angiosarcoma that arises from the breast parenchyma and is not associated with radiation exposure.


Metastatic HER2-Negative Breast Carcinoma

HER2-negative breast adenocarcinoma that has spread to another anatomic site.


Recurrent HER2-Positive Breast Carcinoma

The reemergence of HER2-positive breast carcinoma after a period of remission.


Anatomic Stage 0 Breast Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Stage IIIC Breast Cancer AJCC v6

Stage IIIC Breast Cancer was added in the 6th Edition AJCC Staging Manual, on the basis of metastasis to the infraclavicular lymph nodes (N3) plus any T, M0.


Hormone Receptor-Positive Breast Carcinoma

Breast adenocarcinoma that is positive for estrogen or progesterone receptors.


Refractory Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.


breast leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, arising from the breast. It is characterized by a proliferation of neoplastic spindle cells.


Malignant nipple neoplasm male

A malignant neoplasm that affects the area of the nipple in males.


Metastatic Breast Neuroendocrine Neoplasm

A neuroendocrine neoplasm that arises from the breast and has metastasized to another anatomic site.


Inflammatory carcinoma of breast stage III

Inflammatory breast carcinoma is classified as AJCC Stage IIIB (T4d) unless other criteria indicate more advanced staging.


High Grade Breast Mucoepidermoid Carcinoma

An aggressive mucoepidermoid carcinoma characterized by the presence of focal necrosis and high mitotic activity.  Lymph node and distant metastases are common.  The prognosis is usually poor.


Postradiation Breast Angiosarcoma

A malignant vascular neoplasm arising from the skin of the breast secondary to radiation treatment for breast cancer.


Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma

An invasive ductal breast carcinoma associated with an invasive lobular carcinomatous component.


Multicentric Breast Carcinoma

A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from different clones and are usually located in different quadrants of the breast.


Breast Cancer by AJCC v8 Prognostic Stage

A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)


Stage IIIB Breast Carcinoma

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Locally Advanced HER2-Negative Breast Carcinoma

HER2-negative breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Prognostic Stage IIB Breast Cancer AJCC v8

Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Male Breast Carcinoma

A rare invasive carcinoma that arises from the male breast. Morphologically, it is similar to the invasive carcinomas that arise from the female breast. It usually develops in the retroareolar region.


Anatomic Stage II Breast Cancer AJCC v8

Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Low Grade Breast Adenosquamous Carcinoma

A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.


Refractory Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that is resistant to treatment.


Noninfiltrating intraductal papillary adenocarcinoma (morphologic abnormality)

Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)


HER2-Low Breast Carcinoma

Breast adenocarcinoma defined by low expression of HER2 (IHC1+ or IHC2+; FISH negative).


Metastatic Breast Signet Ring Cell Carcinoma

A signet ring cell carcinoma that arises from the breast and has metastasized to other anatomic sites.


Breast adenocarcinoma metastatic

An adenocarcinoma that arises from the breast and has metastasized to another anatomic site.


Stage II Breast Cancer AJCC v6 and v7

Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Inflammatory carcinoma of breast recurrent

The reemergence of inflammatory carcinoma of the breast after a period of remission


Breast Carcinoma with Choriocarcinomatous Features

An invasive ductal breast carcinoma, not otherwise specified, characterized by increased levels of human beta-chorionic gonadotropin in the serum.  Morphologic evidence of choriocarcinomatous differentiation is rare.


Prognostic Stage II Breast Cancer AJCC v8

Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Carcinoma in situ of female breast

A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the female breast.


Recurrent Breast Angiosarcoma

The reemergence of breast angiosarcoma after a period of remission.


Anatomic Stage IIA Breast Cancer AJCC v8

Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Malignant neoplasm of nipple of female breast

A malignant neoplasm that affects the area of the nipple in females.


Paget's disease and infiltrating duct carcinoma of breast

Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.


Anatomic Stage IA Breast Cancer AJCC v8

Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Breast Lobular Carcinoma, Tubulolobular Variant

An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.


Hormone Receptor-Negative Breast Carcinoma

Breast adenocarcinoma that is negative for hormone receptors.


Breast sarcoma recurrent

The reemergence of breast sarcoma after a period of remission.


Breast Carcinoma with Osseous Metaplasia

An invasive breast carcinoma showing differentiation towards bone structures.


Breast Polymorphous Adenocarcinoma

A rare, low grade malignant epithelial neoplasm arising from the breast. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern.


Stage III Breast Cancer AJCC v7

Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


BRCA-Associated Breast Carcinoma

Breast carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


Unresectable Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast carcinoma that is not amenable to surgical resection.


Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component

An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.


Prognostic Stage IA Breast Cancer AJCC v8

Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Pleomorphic lobular carcinoma in situ of breast

Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.


Invasive micropapillary carcinoma of breast

An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.


Anatomic Stage IIIB Breast Cancer AJCC v8

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Unilateral Breast Carcinoma

Breast carcinoma of one breast, or one side of the breast.


Carcinoma in situ of male breast

A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the male breast. It includes the entire spectrum of carcinoma in situ observed in the female breast. It usually develops in the retroareolar region.


Paget's disease and intraductal carcinoma of breast

Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.


Stage III Breast Cancer AJCC v6

Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)


Metastatic Breast Lobular Carcinoma

A lobular breast carcinoma that has spread from the original site of growth to another anatomic site.


Refractory Breast Adenocarcinoma

Breast adenocarcinoma that does not respond to treatment.


Invasive Breast Carcinoma by Histologic Grade


Unresectable Breast Carcinoma

Breast carcinoma that is not amenable to surgical resection.


Recurrent HER2-Negative Breast Carcinoma

The reemergence of HER2-negative breast adenocarcinoma after a period of remission.


Breast adenocarcinoma recurrent

The reemergence of breast adenocarcinoma after a period of remission.


PALB2-Associated Breast Carcinoma

Breast carcinoma caused by deleterious germline mutation in the PALB2 gene.


Recurrent Invasive Breast Carcinoma of No Special Type

The reemergence of invasive breast carcinoma of no special type after a period of remission.


Metastatic Breast Carcinoma

A carcinoma that arises from the breast and has metastasized to another anatomic site.


Refractory Breast Lymphoma

Breast lymphoma that is resistant to treatment.


Malignant nipple neoplasm

A malignant neoplasm that affects the area of the nipple.


Breast Ductal Carcinoma In Situ, Comedo Type

Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.


Occult Breast Carcinoma

Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.


Prognostic Stage III Breast Cancer AJCC v8

Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); IIIC: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


solid type ductal carcinoma in situ of breast

Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.


breast liposarcoma

A malignant adipose tissue neoplasm of the breast.


Prognostic Stage IV Breast Cancer AJCC v8

Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


breast sarcoma

A malignant mesenchymal neoplasm that arises from the breast. Representative examples include angiosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, and extraskeletal osteosarcoma.


Breast Carcinoma Metastatic in the Lung

A carcinoma that arises from the breast and has metastasized to the lung.


Invasive Breast Apocrine Carcinoma

An invasive breast adenocarcinoma with cytological and immunophenotypic characteristics of apocrine differentiation in more than 90 percent of the malignant cells.


Anatomic Stage IIIC Breast Cancer AJCC v8

Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Prognostic Stage IIIC Breast Cancer AJCC v8

Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Triple-Negative Breast Inflammatory Carcinoma

Triple-negative breast inflammatory carcinoma that has spread from its original site of growth to another anatomic site.


Carcinoma breast stage I

Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003


Breast Tall Cell Carcinoma with Reversed Polarity

A rare subtype of invasive breast carcinoma characterized by tall columnar cells with reversed nuclear polarity, arranged in solid and solid papillary patterns, most commonly associated with IDH2 p.Arg172 hotspot mutations. (WHO 2019)